AnaptysBio, Inc. ANAB Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | 20.4%+146pp | -125.9%+832pp | -958.3%+161pp | -1,119.4%-1,029pp | |
| EBITDA margin | 20.7%+146pp | -125.3%+829pp | -954.5%+158pp | -1,112.9%-1,024pp | |
| Free cash flow margin | 8.4%+157pp | -148.7%+560pp | -708.8%+10.1pp | -718.9%— | |
| Efficiency | |||||
| Asset turnover | 0.6×+0.4× | 0.2×+0.2× | 0×0.0× | 0×-0.1× | |
| Liquidity | |||||
| Current ratio | 9.1×-0.4× | 9.5×-1.4× | 10.9×-6.3× | 17.2×-17.2× | |
| Quick ratio | 9.1×-0.4× | 9.5×-1.4× | 10.9×-6.3× | 17.2×-17.2× | |
| Cash ratio | 6.2×+3.5× | 2.7×+1.7× | 1×-1.8× | 2.7×-28.1× | |
| Leverage | |||||
| Debt-to-equity | 0×-0.2× | 0.2×0.0× | 0.2×+0.1× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -4.9×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $1.29-48.2% | $2.50-23.7% | $3.27-64.8% | $9.31-28.4% | |
| Valuation | |||||
| Market capitalization | $1.34B+233% | $402.88M-29.2% | $569.24M-35.4% | $881.1M-8.3% | |
| Enterprise value | $1.1B+273% | $295.83M-46.3% | $551.09M-33.5% | $829.24M+70.7% | |
| Price / sales | 5.7×+1.3× | 4.4×-28.8× | 33.2×-52.5× | 85.7×+70.4× | |
| Price / book | 36.1×+30.4× | 5.7×-0.8× | 6.5×+3.1× | 3.4×+0.7× | |
| EV / EBITDA | 22.8×— | —— | —— | —— | |
| EV / sales | 4.7×+1.5× | 3.2×-28.9× | 32.1×-48.5× | 80.6×+72.9× | |
| Free cash flow yield | 1.5%+35.1pp | -33.7%-12.3pp | -21.4%-13.0pp | -8.4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do AnaptysBio, Inc.'s ratios come from?
- Every ratio is computed from AnaptysBio, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.